Results of a Phase 1/2a dose–escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes

Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]

Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Yesid AlvaradoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Kiran NaqviDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Farhad RavandiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Ricardo De LumpaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;

Anjali AdvaniLeukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA;

Sudipto MukherjeeLeukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA;

Aaron GerdsLeukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA;

Hetty E. CarrawayLeukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA;

Aziz NazhaLeukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA;

Hiroyuki IwamuraFUJIFILM Corporation, Tokyo, Japan;

Motohiko MuraseFUJIFILM Corporation, Tokyo, Japan;

Linda BavisottoFUJIFILM Pharmaceuticals U.S.A., Inc, Cambridge, MA, USA

Michael KurmanFUJIFILM Pharmaceuticals U.S.A., Inc, Cambridge, MA, USA

Gary MaierFUJIFILM Pharmaceuticals U.S.A., Inc, Cambridge, MA, USA

Mary JohansenFUJIFILM Pharmaceuticals U.S.A., Inc, Cambridge, MA, USA

Mikkael A. SekeresLeukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA;

References